United States · 
What does Athyrium Capital Management invest in?
Athyrium Capital Management invests most often at Debt and Venture (100% of the rounds on record), in sectors such as Wellness, Health and Tech-enabled Health.
Athyrium Capital Management highlights
- 01
5 rounds on record
- 02
Mostly Debt and Venture: 100% of its rounds
- 03
Sole investor in 4 rounds, median $48M
What they do
Athyrium Capital Management is a leading investment management platform dedicated to global opportunities in the healthcare sector.From their own website
- Type
- Private equity (from a list, unverified)
- Cheque size
- Not stated
- Stages
- SeedSeries ASeries B
- Sectors
- WellnessHealthTech-enabled Health
- Based in
- New York, United States
- Cold pitches
- Not accepted
The record
Every round we can evidence, newest first5 appearances
- 2019
1 round
- Mar
- 2018
1 round
- Jul
- 2015
2 rounds
- Sept
- Mar
- 2014
1 round
- Jul
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
The team
Named by the firm itself, on a filing, its Form ADV or its company registration5 named
ACAndrew Cooper HymanChief Compliance OfficeriForm ADV
CACourtney Anne PaulVice President and Assistant SecretaryiForm ADV
EMElin Mydland StrongSenior Vice PresidentiForm ADV
JAJeffrey Allen FerrellPresidentiForm ADV
RJRashida Jamelia AdamsVice PresidentiForm ADV
We also hold 35 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
What the register says
From the firm's own filings with the SEC, which it must file accurately by law
$2.5Bassets it managesOct 2026
Registeredinvestment adviserfull reporting to the SEC
- Legal name
- Athyrium Capital Management LP
- SEC number
- CRD 161528
Funds on its Form ADV
8 private funds, $2.9B in gross assets · filed Sept 2024
Hedge 7Private equity 1
- Athyrium Opportunities Fund IV Master (NON-US) L.P.Hedge24 investors$1.1B
- Athyrium Opportunities Fund III Master (NON-US) L.P.Hedge16 investors$726M
- Athyrium Opportunities Fund III L.P.Hedge25 investors$289M
- Athyrium Opportunities Fund II Master (NON-US) L.P.Hedge21 investors$249M
- Athyrium Opportunities Fund IV L.P.Hedge5 investors$193M
- Athyrium Opportunities Fund II L.P.Hedge32 investors$153M
- Athyrium Opportunities IV Co-Invest A L.P.Private equity1 investor$102M
- Athyrium Opportunities Fund II-B Master L.P.Hedge2 investors$46M
What they claim to have backed
From their own portfolio page (on their website)
26 of 60 we have independently watched raise
AgendiaAlcrestaAmrytpharmaBioclinicaBionpharmaBridgebioClarioCloverhealthDermiraHlstherapeuticsHorizonpharmaMedicreaNavihealthOmerosOptinoseOuitherapeuticsPortolaPumabiotechnologySecurabioTriabeautyUmotifUniversalbiosensorsValnevaVillagemdVitahealthZealandpharmaAlvogenAmagpharmaApolloendoAquadermatologyArisglobalAzurityBasfBasileaBendbioscienceBioratherapeuticsCalliditasCentinelspineChoicehealthathomeCipherpharmaCoherusCompletehealthDupagemedicalgroupElaraEsperionGalenicaGentivahsHalozymeHealthsunHeartlandvetpartnersIndiviorInnopharmaincInnovacarehealthIronwoodpharmaLeonmedicalcentersLongevityhealthplanObhgParatekpharmaPharmericaPtcbioand 15 more
Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.